PLAINSBORO, New Jersey, USA / BAGSVÆRD, Denmark, July 11, 2026
Novo Nordisk has announced positive long-term Phase 3 results for its investigational denecimig (Mim8) from the FRONTIER4 extension study, demonstrating encouraging long-term safety and efficacy in children, adolescents, and adults with hemophilia A, with or without inhibitors. Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, the interim findings showed that denecimig maintained low annualized bleeding rates (ABRs), favorable long-term safety, and flexible dosing options, including once-weekly, once-every-two-weeks, and once-monthly administration. The investigational Factor VIIIa (FVIIIa) mimetic antibody, currently under U.S. FDA review, demonstrated consistent clinical performance across all patient groups and dosing schedules without new safety concerns. Novo Nordisk also presented positive Phase 3 explorer10 data showing concizumab significantly reduced bleeding rates in children with hemophilia A or B with inhibitors, reinforcing the company’s commitment to advancing next-generation therapies for rare bleeding disorders.
FRONTIER4 Demonstrates Durable Safety and Bleeding Protection
The ongoing Phase 3 FRONTIER4 extension study evaluated 426 participants aged one year and older who continued denecimig prophylaxis after completing earlier FRONTIER clinical trials. The interim analysis confirmed that the long-term safety profile remained consistent with previous studies, with no clinical evidence of neutralizing antibodies and only low rates of mild, transient injection-site reactions across all age groups. Efficacy outcomes also remained highly encouraging, with estimated annualized bleeding rates of 0.75 in adults and adolescents and 0.37 in children, regardless of inhibitor status or dosing frequency. Approximately 71% of adults and adolescents and 89% of children experienced zero treated bleeding episodes while receiving denecimig.
Patient-reported outcomes further demonstrated improvements in joint pain, reduced treatment burden, and high satisfaction with the denecimig pen injector, with the majority of participants reporting that the device was easy to prepare and administer. Additional analyses also showed that denecimig restored thrombin generation into the normal range without excessive clotting activity, providing further evidence supporting its mechanism of action and long-term therapeutic potential.
Novo Nordisk Expands Hemophilia Innovation Pipeline
Advertisement
Alongside the FRONTIER4 findings, Novo Nordisk presented the first Phase 3 explorer10 results evaluating concizumab prophylaxis in children under 12 years of age with hemophilia A or B and inhibitors. The study demonstrated an 82% reduction in annualized bleeding rates compared with previous on-demand treatment, highlighting the potential of concizumab to improve disease management in pediatric patients with limited treatment options. While most adverse events were mild and manageable, the results further strengthened the growing body of evidence supporting Novo Nordisk’s hemophilia portfolio. Denecimig, a subcutaneous bispecific FVIIIa-mimetic antibody, is designed to restore blood clotting by bridging Factor IXa and Factor X, mimicking the activity of activated Factor VIII.
The therapy is currently under Biologics License Application (BLA) review by the U.S. Food and Drug Administration, following its submission in 2025. With positive long-term Phase 3 evidence now available across multiple dosing schedules and patient populations, Novo Nordisk continues to strengthen its position in rare blood disorders, advancing innovative therapies that aim to reduce bleeding episodes, improve treatment flexibility, and enhance quality of life for people living with hemophilia A worldwide.
Source: Novo Nordisk press release
